Kenneth M Boucher

List of Publications by Year
in descending order

72 papers	3,378 citations	147566 31 h-index	149479 56 g-index
74 all docs	74 docs citations	74 times ranked	6761 citing authors

#	Article	IF	Citations
1	Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell, 2011, 19, 441-455.	7.7	452
2	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. BMC Medical Genomics, 2012, 5, 44.	0.7	250
3	Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10149-10154.	3.3	246
4	First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Molecular Therapy, 2010, 18, 442-446.	3.7	244
5	Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics, 2008, 9, 523.	1.2	190
6	Expanding Access to BRCA1/2 Genetic Counseling with Telephone Delivery: A Cluster Randomized Trial. Journal of the National Cancer Institute, 2014, 106, dju328-dju328.	3.0	105
7	Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma. Journal of Clinical Oncology, 2005, 23, 7168-7177.	0.8	91
8	Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma. Pancreas, 2013, 42, 193-197.	0.5	86
9	Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. Journal of Cancer Survivorship, 2014, 8, 60-69.	1.5	74
10	Agreement in Risk Prediction Between the 21â€Gene Recurrence Score Assay (Onco type DXÂ®) and the PAM50 Breast Cancer Intrinsic Classifierâ„¢ in Earlyâ€Stage Estrogen Receptorâ€"Positive Breast Cancer. Oncologist, 2012, 17, 492-498.	1.9	71
11	UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis, 2004, 26, 249-257.	1.3	68
12	Clinical germline genetic testing for melanoma.. Lancet Oncology, The, 2004, 5, 314-319.	5.1	62
13	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2605-2610.	1.1	55
14	Estimating an oncogenetic tree when false negatives and positives are present. Mathematical Biosciences, 2002, 176, 219-236.	0.9	48
15	Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: The national experience. Liver Transplantation, 2012, 18, 423-433.	1.3	48
16	Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Hpb, 2014, 16, 670-676.	0.1	48
17	Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. Journal of Cancer Survivorship, 2015, 9, 115-125.	1.5	47
18	AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular Cancer Research, 2019, 17, 1787-1800.	1.5	46

#	Article	IF	Citations
19	Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Advances, 2018, 2, 381-389.	2.5	45
20	Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	3.2	45
21	Use of Oral<i>N</i>-Acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress: Towards a Novel Paradigm for Melanoma Chemoprevention. Clinical Cancer Research, 2009, 15, 7434-7440.	3.2	42
22	Distinct Molecular Phenotype of Sporadic Colorectal Cancers Among Young Patients Based on Multiomics Analysis. Gastroenterology, 2020, 158, 1155-1158.e2.	0.6	42
23	American Founder Mutation for Attenuated Familial Adenomatous Polyposis. Clinical Gastroenterology and Hepatology, 2008, 6, 46-52.	2.4	41
24	Awareness and Preferences Regarding <i>BRCA1/2</i> Genetic Counseling and Testing Among Latinas and Non–Latina White Women at Increased Risk for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling, 2011, 20, 625-638.	0.9	41
25	Reduction in nevus biopsies in patients monitored by total body photography. Journal of the American Academy of Dermatology, 2016, 75, 135-143.e5.	0.6	39
26	Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecologic Oncology, 2015, 136, 521-528.	0.6	38
27	Selenium for the Prevention of Cutaneous Melanoma. Nutrients, 2013, 5, 725-749.	1.7	37
28	Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes and Cancer, 2009, 48, 1-9.	1.5	36
29	Feasibility and Acceptability of a Tai Chi Chih Randomized Controlled Trial in Senior Female Cancer Survivors. Integrative Cancer Therapies, 2013, 12, 464-474.	0.8	36
30	A functional assay–based procedure to classify mismatch repair gene variants in Lynch syndrome. Genetics in Medicine, 2019, 21, 1486-1496.	1.1	36
31	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 2015, 15, 15.	1.2	35
32	EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genetics, 2012, 205, 304-312.	0.2	34
33	Diverse Non-genetic, Allele-Specific Expression Effects Shape Genetic Architecture at the Cellular Level in the Mammalian Brain. Neuron, 2017, 93, 1094-1109.e7.	3.8	34
34	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 3466-3478.	0.4	32
35	Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genetics, 2012, 205, 391-404.	0.2	31
36	Isolation of Circulating MicroRNAs from Microvesicles Found in Human Plasma. Methods in Molecular Biology, 2014, 1102, 641-653.	0.4	29

#	Article	IF	Citations
37	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	0.9	27
38	A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 2013, 79, 307-311.	0.9	23
39	Long-term health effects among testicular cancer survivors. Journal of Cancer Survivorship, 2016, 10, 1051-1057.	1.5	23
40	A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 214-219.	0.5	22
41	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 2021, 21, 510.	1.1	21
42	Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Journal of Clinical Bioinformatics, 2011, 1, 37.	1.2	20
43	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology, 2014, 9, 195-204.	1.7	20
44	A Phase II Randomized Placebo-Controlled Trial of Oral *N*-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress *In Vivo*. Cancer Prevention Research, 2017, 10, 36-44.	0.7	20
45	A Genome-Wide Study Replicates Linkage of 3p22-24 to Extreme Longevity in Humans and Identifies Possible Additional Loci. PLoS ONE, 2012, 7, e34746.	1.1	19
46	Multi-omics Analysis Reveals Adipose–tumor Crosstalk in Patients with Colorectal Cancer. Cancer Prevention Research, 2020, 13, 817-828.	0.7	19
47	Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. Journal of Investigative Dermatology, 2021, 141, 132-141.e3.	0.3	18
48	Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs, 2019, 37, 482-489.	1.2	17
49	Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theoretical Biology and Medical Modelling, 2014, 11, 34.	2.1	16
50	Two integrated and highly predictive functional analysis-based procedures for the classification of MSH6 variants in Lynch syndrome. Genetics in Medicine, 2020, 22, 847-856.	1.1	16
51	Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prevention Research, 2018, 11, 4-15.	0.7	15
52	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 2104-2110.	3.2	15
53	Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. Hpb, 2010, 12, 352-358.	0.1	13
54	A Decade of Melanomas: Identification of Factors Associated with Delayed Detection in an Academic Group Practice. Dermatologic Surgery, 2011, 37, 1620-1630.	0.4	13

#	ARTICLE	IF	CITATIONS
55	A Population-Based Study of Childhood Cancer Survivors' Body Mass Index. Journal of Cancer Epidemiology, 2014, 2014, 1-10.	0.5	13
56	Factors associated with early adoption of the HPV vaccine in US male adolescents include Hispanic ethnicity and receipt of other vaccines. Preventive Medicine Reports, 2016, 4, 98-102.	0.8	13
57	Precision-Exercise-Prescription in patients with lung cancer undergoing surgery: rationale and design of the PEP study trial. BMJ Open, 2018, 8, e024672.	0.8	13
58	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	1.9	13
59	Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience. Cancer Medicine, 2015, 4, 651-660.	1.3	12
60	Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. Journal of Dermatology, 2020, 47, 342-347.	0.6	12
61	ONCOGENETIC TREES. Series in Mathematical Biology and Medicine, 2008, , 1-24.	0.1	10
62	ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals, 2020, 13, 7.	1.7	8
63	Sampling of melanocytic nevi for research purposes: A prospective, pilot study to determine effect on diagnosis. Journal of the American Academy of Dermatology, 2008, 59, 814-821.	0.6	7
64	The Effect of Previsit Education in Breast Cancer Patients: A Study of a Shared-decision-making Tool. American Surgeon, 2016, 82, 259-265.	0.4	7
65	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e169-e172.	0.9	7
66	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 316-320.	0.9	5
67	Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma Research, 2020, 30, 247-251.	0.6	5
68	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors. Blood, 2021, 138, 143-143.	0.6	5
69	Powering a prospective melanoma chemoprevention trial in high-risk cohorts. International Journal of Dermatology, 2019, 58, e232-e234.	0.5	3
70	Low accuracy of self-reported family history of melanoma in high-risk patients. Familial Cancer, 2021, 20, 41-48.	0.9	3
71	A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage. Cancer Prevention Research, 2022, 15, 129-138.	0.7	1
72	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 308-308.	0.8	0